Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v17-FR Version v3-EN
Language French English
Date Updated 2021-05-06 2020-07-15
Drug Identification Number 02354632 02354632
Brand name TEVA-ROSUVASTATIN TEVA-ROSUVASTATIN
Common or Proper name ROSUVASTATIN 40MG TAB ROSUVASTATIN 40MG TAB
Company Name TEVA CANADA LIMITED TEVA CANADA LIMITED
Ingredients ROSUVASTATIN ROSUVASTATIN
Strength(s) 40MG 40MG
Dosage form(s) TABLET TABLET
Route of administration ORAL ORAL ORAL ORAL
Packaging size p pack 30's p pack 30's
ATC code C10AA C10AA
ATC description LIPID MODIFYING AGENTS, PLAIN LIPID MODIFYING AGENTS, PLAIN
Reason for shortage Shortage of an inactive ingredient or component. Shortage of an inactive ingredient or component.
Anticipated start date
Actual start date 2020-07-14 2020-07-14
Estimated end date 2021-04-30 2020-12-31
Actual end date 2021-05-05
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments Allocating 100% of Teva market for duration of risk period. Allocating 100% of Teva market until Sep 2020
Health Canada comments